Disclosed is a treatment of estrogen-deficiency related complaints in
females that exhibit these complaints while they are on treatment with a
drug which prevents the synthesis of endogenous estrogen. Such drugs are,
e.g., anti-cancer drugs such as aromatase inhibitors. The invention
resides in the use of tibolone, which has an unexpectedly beneficial
working in this particular patient group in that it does not stimulate
breast, while preventing bone loss and relieving climacteric complaints
in a patient group in which this is more difficult than in any other
group due to the nature of the concomitant cancer treatment (no
circulating estrogen making for a higher severity of the complaints, the
lack of effect on the estrogen receptor making for an increased risk
associated with estrogenic breast stimulation once estrogen-like
compounds are administered.
